We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-5.61%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.67B
AUM Growth
-$263M
Cap. Flow
-$103M
Cap. Flow %
-3.85%
Top 10 Hldgs %
36.14%
Holding
81
New
10
Increased
17
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$74.9M
2
JNJ icon
Johnson & Johnson
JNJ
+$44.2M
3
BDX icon
Becton Dickinson
BDX
+$41.6M
4
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$30.5M
5
MOH icon
Molina Healthcare
MOH
+$22.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$124M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.3M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$41.5M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$33.6M
5
HCA icon
HCA Healthcare
HCA
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 92.79%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OM icon
1
Outset Medical
OM
$74.9M
$128M 4.77%
187,379
-8,638
-4% -$5.2M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$115M 4.3%
1,091,840
– –
RCUS icon
3
Arcus Biosciences
RCUS
$3.57B
$108M 4.05%
3,431,010
– –
JNJ icon
4
Johnson & Johnson
JNJ
$635B
$104M 3.88%
584,883
+259,911
+80% +$44.2M
CNC icon
5
Centene
CNC
$31.3B
$93.7M 3.5%
1,112,480
– –
CYTK icon
6
Cytokinetics
CYTK
$11B
$90.7M 3.39%
2,465,016
– –
LLY icon
7
Eli Lilly
LLY
$1.07T
$85.5M 3.2%
298,643
– –
GILD icon
8
CALL
Gilead Sciences
GILD
$161B
$84M 3.14%
+1,412,500
New +$90.3M
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.9B
$80.4M 3.01%
+516,406
New +$74.9M
IRTC icon
10
iRhythm Holdings
IRTC
$3.59B
$77.7M 2.91%
493,721
-30,261
-6% -$3.89M
HUM icon
11
Humana
HUM
$46.7B
$72.3M 2.7%
166,066
+26,646
+19% +$11.1M
AVTR icon
12
Avantor
AVTR
$7.81B
$70.3M 2.63%
2,079,657
– –
PFE icon
13
Pfizer
PFE
$140B
$69.5M 2.6%
1,343,384
– –
UHS icon
14
Universal Health Services
UHS
$9.43B
$64M 2.39%
441,336
-34,004
-7% -$4.7M
UNH icon
15
UnitedHealth
UNH
$382B
$56.9M 2.13%
111,554
– –
BMRN icon
16
BioMarin Pharmaceuticals
BMRN
$11.5B
$55.4M 2.07%
718,495
+253,555
+55% +$21.2M
DHR icon
17
Danaher
DHR
$135B
$51.5M 1.93%
198,178
– –
IQV icon
18
IQVIA
IQV
$34.7B
$51.3M 1.92%
221,696
-16,343
-7% -$3.87M
ICUI icon
19
ICU Medical
ICUI
$3.93B
$49.1M 1.84%
220,587
– –
MOH icon
20
Molina Healthcare
MOH
$10.3B
$48M 1.79%
143,779
+73,691
+105% +$22.7M
MYGN icon
21
Myriad Genetics
MYGN
$530M
$47.4M 1.77%
1,882,357
-143,324
-7% -$3.67M
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$47M 1.76%
649,513
+164,378
+34% +$11.9M
THC icon
23
Tenet Healthcare
THC
$20.1B
$46.8M 1.75%
544,583
+18,656
+4% +$1.53M
BDX icon
24
Becton Dickinson
BDX
$43.1B
$41.9M 1.57%
+161,533
New +$41.6M
DVAX
25
DELISTED
Dynavax Technologies
DVAX
$41.3M 1.54%
3,805,370
– –
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q1 2022 Portfolio in Review

As of Q1 2022, PFM Health Sciences held 81 positions worth $2.67B, down 8.9% from $2.94B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $103M in Q1 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was AbbVie, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Jazz Pharmaceuticals worth $80.4M.

  • PFM Health Sciences's largest Q1 2022 buy was Jazz Pharmaceuticals: 516,406 shares worth $80.4M.
  • PFM Health Sciences added most to Johnson & Johnson in Q1 2022, an estimated $44.2M increase.
  • PFM Health Sciences's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $29M.
  • PFM Health Sciences fully exited AbbVie in Q1 2022, selling an estimated $124M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $2.67B portfolio in Q1 2022.
  • PFM Health Sciences opened 10 new positions and closed 13 in Q1 2022.
  • PFM Health Sciences's portfolio value fell 8.9% quarter-over-quarter to $2.67B.

Based on PFM Health Sciences's 13F filing for Q1 2022, filed 16 May 2022.